Mayne Pharma Group Limited

ASX:MYX.AX

Sector

🏥 Health Care

Industries

🧬 Biotechnology

💊 Pharmaceuticals

Location

Australia

Market Cap

USD 264.24 M

Share Price

USD 3.25

Avg Daily Volume

675,172

Change (1 day)

-1.84%

Change (1 year)

27.15%

Change (YTD)

5.73%

Mayne Pharma Group Limited EBITDA for the year ending June 30, 2024: USD -77.96 M

Mayne Pharma Group Limited EBITDA is USD -77.96 M for the year ending June 30, 2024, a -39.55% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Mayne Pharma Group Limited EBITDA for the year ending June 30, 2023 was USD -128.98 M, a 136.92% change year over year.
Mayne Pharma Group Limited EBITDA for the year ending June 30, 2022 was USD -54.44 M, a -60.19% change year over year.
Mayne Pharma Group Limited EBITDA for the year ending June 30, 2021 was USD -136.76 M, a 482.16% change year over year.
Mayne Pharma Group Limited EBITDA for the year ending June 30, 2020 was USD -23.49 M, a -86.13% change year over year.